Posts by Peter W. PENG

Editor’s Note: This September, the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2025), one of China’s most prestigious oncology conferences, was successfully held in Jinan. During…

Editor’s Note: Immunotherapy has become an important treatment modality in breast cancer, achieving breakthroughs by modulating the immune system to mount anti-tumor responses. At the 8th Conference on Oncology Precision…

Editor’s Note: With China’s rapidly aging population, cancer prevention and treatment face new challenges and opportunities. As the birthplace of modern oncology in China, Tianjin Medical University Cancer Institute and…

For patients with hormone receptor–positive (HR+) early breast cancer, when intensifying adjuvant endocrine therapy with a CDK4/6 inhibitor, should abemaciclib or ribociclib be preferred? At the 2025 Summer Breast Cancer Forum · Northern Salon, Professors Bin Song of Shanxi Bethune Hospital and Yuan Peng of Peking University People’s Hospital debated this question during the “Debate” session. Here, in Oncology Frontier’s “In-Depth” column, they share their perspectives supported by evidence.